Rational Design of Vaccine Molecules to Prevent Pertussis

No abstract is available for this paper.

• Publication year

  1995

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1007/978-1-4613-0357-2_9
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Formaldehyde treatment of proteins can constrain presentation to T cells by limiting antigen processing

  1994cited by this paper
• Comparative study of a whole-cell pertussis vaccine and a recombinant acellular pertussis vaccine. The Italian Multicenter Group for the Study of Recombinant Acellular Pertussis Vaccine.

  1994cited by this paper
• Immunogenicity of an acellular pertussis vaccine composed of genetically inactivated pertussis toxin combined with filamentous hemagglutinin and pertactin in infants and children.

  1993cited by this paper
• Acellular pertussis vaccine composed of genetically inactivated pertussis toxin: safety and immunogenicity in 12- to 24- and 2- to 4-month-old children.

  1992cited by this paper
• Interaction of the pertussis toxin peptide containing residues 30-42 with DR1 and the T-cell receptors of 12 human T-cell clones.

  1992cited by this paper
• Phase I clinical trial of an acellular pertussis vaccine composed of genetically detoxified pertussis toxin combined with FHA and 69 kDa.

  1991cited by this paper
• Properties of pertussis toxin mutant PT-9K/129G after formaldehyde treatment

  1991cited by this paper
• New Generation Vaccines

  1990cited by this paper
• Metabolic, humoral, and cellular responses in adult volunteers immunized with the genetically inactivated pertussis toxin mutant PT- 9K/129G

  1990cited by this paper
• Characterization of genetically inactivated pertussis toxin mutants: candidates for a new vaccine against whooping cough

  1990cited by this paper
• Haemophilus influenzae infections and whooping cough.

  1990cited by this paper
• Human T cell clones define S1 subunit as the most immunogenic moiety of pertussis toxin and determine its epitope map

  1989cited by this paper
• Mutants of pertussis toxin suitable for vaccine development.

  1989cited by this paper
• Pertussis: the disease and new diagnostic methods

  1988cited by this paper
• Mortality and morbidity from invasive bacterial infections during a clinical trial of acellular pertussis vaccines in Sweden.

  1988cited by this paper
• Dissecting human T cell responses against Bordetella species

  1988cited by this paper
• Virulence factors of Bordetella pertussis.

  1986cited by this paper
• The concept of pertussis as a toxin‐mediated disease

  1984cited by this paper

• No citing papers are available for this paper.